Aptose Biosciences, Inc. (APTO): Price and Financial Metrics
GET POWR RATINGS... FREE!
APTO Stock Price Chart Interactive Chart >
APTO Price/Volume Stats
|Current price||$0.95||52-week high||$5.78|
|Prev. close||$0.96||52-week low||$0.90|
|Day high||$0.98||Avg. volume||418,242|
|50-day MA||$1.18||Dividend yield||N/A|
|200-day MA||$1.74||Market Cap||87.91M|
Aptose Biosciences, Inc. (APTO) Company Bio
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company was founded in 1986 and is based in Mississauga, Canada.
Most Popular Stories View All
APTO Latest News Stream
|Loading, please wait...|
APTO Latest Social Stream
View Full APTO Social Stream
Latest APTO News From Around the Web
Below are the latest news stories about Aptose Biosciences Inc that investors may wish to consider to help them evaluate APTO as an investment opportunity.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
I’ve been bullish on Aptose Biosciences (APTO) for some time, but have also tried to make clear that I view this as an extremely risky play on potentially class-leading drugs for hematologic oncology. So far, that bullishness has not been rewarded at all, as disappointing clinical updates have led investors...
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners Corporate Access Event. The Aptose management team will be hosting investor meetings during
Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..
APTO Price Returns